JP2017537070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537070A5 JP2017537070A5 JP2017522084A JP2017522084A JP2017537070A5 JP 2017537070 A5 JP2017537070 A5 JP 2017537070A5 JP 2017522084 A JP2017522084 A JP 2017522084A JP 2017522084 A JP2017522084 A JP 2017522084A JP 2017537070 A5 JP2017537070 A5 JP 2017537070A5
- Authority
- JP
- Japan
- Prior art keywords
- immune checkpoint
- stranded antisense
- cancer
- antisense oligonucleotide
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068141P | 2014-10-24 | 2014-10-24 | |
| US62/068141 | 2014-10-24 | ||
| PCT/EP2015/074271 WO2016062722A1 (en) | 2014-10-24 | 2015-10-20 | Combination |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537070A JP2017537070A (ja) | 2017-12-14 |
| JP2017537070A5 true JP2017537070A5 (enExample) | 2018-11-29 |
| JP6687612B2 JP6687612B2 (ja) | 2020-04-22 |
Family
ID=54347516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522084A Active JP6687612B2 (ja) | 2014-10-24 | 2015-10-20 | 組合せ |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190194654A1 (enExample) |
| EP (2) | EP3209778B1 (enExample) |
| JP (1) | JP6687612B2 (enExample) |
| KR (3) | KR20170072928A (enExample) |
| CN (2) | CN115920007A (enExample) |
| AU (1) | AU2015335029B2 (enExample) |
| CA (1) | CA2965034C (enExample) |
| DK (1) | DK3209778T3 (enExample) |
| ES (1) | ES2727154T3 (enExample) |
| HU (1) | HUE043227T2 (enExample) |
| IL (2) | IL251813A0 (enExample) |
| PL (1) | PL3209778T3 (enExample) |
| RU (1) | RU2744841C2 (enExample) |
| SG (2) | SG11201703219WA (enExample) |
| TR (1) | TR201906415T4 (enExample) |
| WO (1) | WO2016062722A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA023913B1 (ru) | 2009-05-11 | 2016-07-29 | БЕРГ ФАРМА ЭлЭлСи | Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния |
| WO2012138765A1 (en) | 2011-04-04 | 2012-10-11 | Berg Pharma Llc | Methods of treating central nervous system tumors |
| EA032775B1 (ru) | 2013-04-08 | 2019-07-31 | Берг Ллк | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 |
| SG10201907816RA (en) | 2013-09-04 | 2019-09-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
| MX360295B (es) * | 2014-05-29 | 2018-10-29 | Medimmune Llc | Proteinas de fusion del ligando de ox40 (ox40l) y sus usos. |
| EP3209778B1 (en) * | 2014-10-24 | 2019-04-03 | Astrazeneca AB | Combination |
| CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CN115109158A (zh) | 2015-05-07 | 2022-09-27 | 阿吉纳斯公司 | 抗ox40抗体及其使用方法 |
| CN108368170B (zh) | 2015-07-13 | 2022-04-15 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| US20170189350A1 (en) | 2015-11-16 | 2017-07-06 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| EP3411407B1 (en) | 2016-02-05 | 2024-04-03 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物 |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| US11753463B2 (en) | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
| US20180021270A1 (en) * | 2016-07-21 | 2018-01-25 | Berg Llc | Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| EP3529264B1 (en) | 2016-10-24 | 2022-03-09 | Orionis Biosciences BV | Targeted mutant interferon-gamma and uses thereof |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
| US20190256603A1 (en) * | 2016-11-11 | 2019-08-22 | Medimmune, Llc | Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| US11285149B2 (en) | 2017-07-28 | 2022-03-29 | Dana-Farber Cancer Institute, Inc. | Enhanced immunotherapy of cancer using targeted transcriptional modulators |
| US20200354424A1 (en) | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| SG11202006021SA (en) * | 2018-02-12 | 2020-08-28 | Codiak Biosciences Inc | Methods and compositions for macrophage polarization |
| JPWO2019177159A1 (ja) * | 2018-03-15 | 2021-02-25 | 国立大学法人北海道大学 | 癌免疫療法併用剤 |
| WO2019191429A2 (en) | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Identification of epigenetic alterations in dna isolated from exosomes |
| EP3784279A1 (en) * | 2018-04-25 | 2021-03-03 | MedImmune Limited | Formulations of human anti-pd-l1 antibodies |
| EP3890773A4 (en) | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
| CN109675040B (zh) * | 2018-12-31 | 2021-07-30 | 清华大学 | 治疗乳腺癌的组合物及其应用 |
| WO2020156500A1 (zh) * | 2019-01-31 | 2020-08-06 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
| EP3946300A4 (en) * | 2019-04-02 | 2023-01-18 | Board of Regents, The University of Texas System | COMBINATIONS OF TRANSCRIPTION INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS TO TREAT DISEASE |
| JPWO2020218432A1 (enExample) * | 2019-04-26 | 2020-10-29 | ||
| JPWO2021039616A1 (enExample) * | 2019-08-23 | 2021-03-04 | ||
| JP2022550783A (ja) * | 2019-09-30 | 2022-12-05 | アストラゼネカ・アクチエボラーグ | 併用処置 |
| US20240091364A1 (en) * | 2019-10-09 | 2024-03-21 | City Of Hope | Cancer combination treatments using anti-stat3 nucleic acid conjugates |
| CN114599372A (zh) | 2019-11-04 | 2022-06-07 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| AU2020398177A1 (en) * | 2019-12-05 | 2022-07-07 | Board Of Regents, The University Of Texas System | Exosomes-based therapy for liver fibrosis and other diseases associated with fibrosis |
| US20230183366A1 (en) * | 2020-05-13 | 2023-06-15 | Inserm (Institut National De La Santé Et De La Recherch Médicale) | Recombinant proteins with ox40 activating properties |
| US20230364127A1 (en) * | 2020-10-06 | 2023-11-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| JP2025509502A (ja) * | 2022-03-15 | 2025-04-11 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ｓｔａｔ３標的化オリゴヌクレオチドおよびｐｄ－ｌ１阻害剤の組み合わせ |
| EP4649173A1 (en) | 2023-01-13 | 2025-11-19 | Akrivia Biomedics Limited | Method of profiling diseases |
| NL2037811B1 (en) | 2024-05-29 | 2025-12-12 | Univ Oslo | Treatment for Cancer |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| US6159694A (en) | 1999-04-08 | 2000-12-12 | Isis Pharmaceuticals Inc. | Antisense modulation of stat3 expression |
| BR0013542A (pt) | 1999-08-23 | 2002-05-14 | Dana Farber Cancer Inst Inc | Moléculas b7-4 e usos para as mesmas |
| US7158164B2 (en) | 2003-08-29 | 2007-01-02 | Fuji Photo Film Co., Ltd. | Thermal development method and apparatus |
| JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ， インコーポレーテッド | ４’−チオヌクレオシドおよびオリゴマー化合物 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| LT2650020T (lt) | 2005-05-06 | 2016-12-12 | Providence Health & Services - Oregon | Trimerinio ox40-immunoglobulino sulietas baltymas ir naudojimo būdai |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| US20070243184A1 (en) | 2005-11-08 | 2007-10-18 | Steven Fischkoff | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| WO2008109494A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting stat3 gene expression and uses thereof |
| US20100298409A1 (en) | 2007-09-17 | 2010-11-25 | Intradigm Corporation | Compositions comprising stat3 sirna and methods of use thereof |
| US20100285039A1 (en) | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| SG193504A1 (en) | 2011-04-01 | 2013-10-30 | Isis Pharmaceuticals Inc | Modulation of signal transducer and activator of transcription 3 (stat3) expression |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| WO2013119202A1 (en) | 2012-02-06 | 2013-08-15 | Providence Health & Services - Oregon | Cancer treatment and monitoring methods using ox40 agonists |
| HK1205691A1 (en) | 2012-03-02 | 2015-12-24 | Providence Health & Services - Oregon | Dual ox40 agonist/il-2 cancer therapy methods |
| WO2013134467A1 (en) * | 2012-03-07 | 2013-09-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
| PL2920308T3 (pl) | 2012-10-31 | 2019-06-28 | Ionis Pharmaceuticals, Inc. | Leczenie nowotworu |
| EP3209778B1 (en) * | 2014-10-24 | 2019-04-03 | Astrazeneca AB | Combination |
-
2015
- 2015-10-20 EP EP15784628.8A patent/EP3209778B1/en active Active
- 2015-10-20 RU RU2017117664A patent/RU2744841C2/ru active
- 2015-10-20 SG SG11201703219WA patent/SG11201703219WA/en unknown
- 2015-10-20 HU HUE15784628A patent/HUE043227T2/hu unknown
- 2015-10-20 DK DK15784628.8T patent/DK3209778T3/da active
- 2015-10-20 KR KR1020177013607A patent/KR20170072928A/ko not_active Ceased
- 2015-10-20 EP EP19166017.4A patent/EP3550019A1/en active Pending
- 2015-10-20 TR TR2019/06415T patent/TR201906415T4/tr unknown
- 2015-10-20 KR KR1020257036604A patent/KR20250161048A/ko active Pending
- 2015-10-20 US US15/521,185 patent/US20190194654A1/en not_active Abandoned
- 2015-10-20 KR KR1020237028459A patent/KR20230128139A/ko not_active Ceased
- 2015-10-20 PL PL15784628T patent/PL3209778T3/pl unknown
- 2015-10-20 ES ES15784628T patent/ES2727154T3/es active Active
- 2015-10-20 JP JP2017522084A patent/JP6687612B2/ja active Active
- 2015-10-20 CN CN202211353077.8A patent/CN115920007A/zh active Pending
- 2015-10-20 WO PCT/EP2015/074271 patent/WO2016062722A1/en not_active Ceased
- 2015-10-20 SG SG10202105879XA patent/SG10202105879XA/en unknown
- 2015-10-20 CA CA2965034A patent/CA2965034C/en active Active
- 2015-10-20 CN CN201580057882.8A patent/CN107106590B/zh active Active
- 2015-10-20 AU AU2015335029A patent/AU2015335029B2/en active Active
-
2017
- 2017-04-20 IL IL251813A patent/IL251813A0/en unknown
-
2022
- 2022-10-13 US US18/046,173 patent/US20230374503A1/en active Pending
-
2023
- 2023-07-23 IL IL304663A patent/IL304663A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537070A5 (enExample) | ||
| RU2017117664A (ru) | Комбинация | |
| Gao et al. | LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non‐small cell lung cancer | |
| Jensen et al. | Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer | |
| JP2018508593A5 (enExample) | ||
| Hainsworth et al. | Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial | |
| Sun et al. | WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy | |
| JP2018516911A5 (enExample) | ||
| Wisdom et al. | Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma | |
| Huang et al. | Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma | |
| JP2017530950A5 (enExample) | ||
| JP2017506227A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2015532292A5 (enExample) | ||
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| FI2547205T3 (fi) | Uusia menetelmiä syövän kantasolujen kohdentamiseksi | |
| Ngoi et al. | A tale of two checkpoints: ATR inhibition and PD-(L) 1 blockade | |
| Liu et al. | MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1 | |
| Wilson et al. | Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer | |
| Rudnick et al. | Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies | |
| JP2017537927A5 (enExample) | ||
| Wakelee et al. | Cooperative Group Research Efforts in Lung Cancer 2008: Focus on Advanced-Stage Non–Small-Cell Lung Cancer | |
| MX2014000204A (es) | Metodo de administracion y tratamiento. | |
| MX358501B (es) | Combinación farmacéutica de sinergia para el tratamiento del carcinoma de célula escamosa de cabeza y cuello. |